Momelotinib

(Ojjaara®)

Ojjaara®

Drug updated on 12/11/2024

Dosage FormTablet (oral; 100 mg, 150 mg, 200 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review/meta-analysis. [1]
  • Spleen Volume Reduction: Momelotinib demonstrated efficacy comparable to ruxolitinib and fedratinib in reducing spleen volume in first-line treatment for myelofibrosis. Pacritinib was less effective in first-line therapy but showed effectiveness in second-line therapy following ruxolitinib exposure.
  • Effect on Anemia and Thrombopenia: Momelotinib exhibited positive effects on anemia and was associated with lower toxicity on platelets compared to fedratinib and ruxolitinib, suggesting a potentially safer profile for managing hematological side effects.
  • Momelotinib demonstrated a favorable safety profile, showing less toxicity on erythrocytes (ANEMIA) and platelets (THROMBOPENIA) compared to other Janus Kinase (JAK) inhibitors such as ruxolitinib and fedratinib, suggesting reduced hematological side effects.
  • Specific safety concerns or adverse effects beyond anemia and thrombopenia were not detailed in the provided abstract.
  • There is no population types or subgroups information available in the reviewed documents.

Product Monograph / Prescribing Information

Document TitleYearSource
Ojjaara (momelotinib) Prescribing Information.2023GlaxoSmithKline Durham, NC

Systematic Reviews / Meta-Analyses